Octopus Biosafety SA Stocks

0.2Last Updated 22.04.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

€ 31.42M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
0.2
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

MCAI SAS designs, develops, manufactures, and market mobile and autonomous robots intended to decontaminate facilities, such as airports, industrial buildings, and public buildings. Its products are also used to aerosolize phytosanitary products and other substances; to atomize liquid substances, such as biocides, phytosanitary solutions, and pesticides; and carry specific modules and equipment, such as detection/monitoring systems, unmanned aircraft systems/drones, etc. The company also provides Octopus Poultry Safe, a robot that assists breeders in monitoring their routine, mapping indoor temperature and relative humidity, CO2/ammonia and sound/brightness levels, and other parameters; and Octopus Biosafety, which provides civil defense/civil protection professionals with a means of microbial contamination prevention and control in case of a pandemic or bioterrorism attack. It offers its products for agro-food, animal healthcare, biotech, security, transport, and defense industries. The company was founded in 1987 and is based in Cholet, France.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks